Sharon Stone Details Heroin-Like Withdrawal After Quitting High-THC Cannabis

Stone Compares Cannabis Withdrawal to Opioid Detox

Sharon Stone said she experienced shaking, nausea, and physical distress severe enough to compare to heroin withdrawal after quitting high-potency marijuana products. The Basic Instinct star, speaking publicly about her cannabis use for the first time, said the withdrawal lasted several days and required medical consultation. Stone didn't specify the THC concentration of the products she used. She described them as "very strong" dispensary vapes purchased in California.

Her account aligns with diagnostic criteria for cannabis withdrawal disorder, added to the DSM-5 in 2013. The condition affects an estimated 12-47% of daily cannabis users who stop abruptly. Rates climb higher among users of concentrates and vapes exceeding 70% THC.

High-Potency Products Drive Withdrawal Risk

Products containing 20% or more THC—now the California dispensary median—carry significantly higher dependence and withdrawal rates than flower-based cannabis used in pre-legalization decades. A 2024 JAMA Psychiatry study found that users of concentrates (dabs, vapes, distillates) were 3.2 times more likely to report withdrawal symptoms than flower-only users, even after controlling for frequency of use.

Clinical literature documents these key withdrawal symptoms:

• Irritability and mood disturbance (reported by 50-95% of patients)
• Sleep disruption and vivid dreams (76%)
• Decreased appetite (65%)
• Physical symptoms: tremor, sweating, nausea, headache (28-45%)
• Peak severity at days 2-6 after cessation, tapering over 2-4 weeks

The syndrome isn't life-threatening, unlike opioid or alcohol withdrawal. But Stone's comparison underscores the subjective severity reported by some patients. Dr. Beatriz Carlini at the University of Washington Alcohol & Drug Abuse Institute noted in 2025 testimony that emergency-department visits for cannabis withdrawal in Washington state tripled between 2020 and 2024. The spike concentrated among users of vape cartridges and dabs.

Regulatory Gap: No Potency Caps in Major Markets

No U.S. state with adult-use legalization currently caps THC potency in flower or concentrates, despite proposals in Colorado, Vermont, and Washington. California's Bureau of Cannabis Control mandates potency labeling but sets no upper limit. Concentrates routinely test at 80-95% THC; vape cartridges at 70-85%. For context, cannabis flower seized at the U.S.-Mexico border in the 1990s averaged 3-4% THC, according to DEA data.

Vermont's 2024 legislative session saw a potency-cap bill (H.270) that would've limited flower to 30% THC and concentrates to 60%. The measure stalled in committee after industry lobbying. Colorado's Marijuana Policy Review Panel recommended a 35% cap for flower in 2023; the legislature hasn't acted. Washington state's Liquor and Cannabis Board opened a public comment period on potency limits in May 2026, with a decision expected in Q4.

Canada imposed a 10mg THC cap per edible package in 2019 but doesn't limit flower or concentrate potency. Uruguay, the first nation to legalize adult-use cannabis in 2013, caps flower sold in pharmacies at 9% THC. Public-health advocates cite it as a harm-reduction model. Industry groups criticize it as driving consumers to the illicit market.

Clinical Recognition and Treatment Gaps

Cannabis withdrawal disorder remains underdiagnosed. Fewer than 15% of U.S. addiction-treatment programs offer cannabis-specific protocols, according to a 2025 SAMHSA survey. Most patients presenting with withdrawal are advised to taper use or quit abruptly without pharmacological support. No FDA-approved medications exist for cannabis withdrawal, though small trials of gabapentin, N-acetylcysteine, and synthetic cannabinoids have shown modest efficacy in reducing irritability and cravings.

Stone said she sought medical advice during her withdrawal but didn't specify the treatment. Anecdotally, clinicians report that patients using high-potency products daily for months or years often require structured tapering over 4-8 weeks to avoid severe symptoms. Telehealth platforms specializing in cannabis-use disorder—including Ophelia, Boulder Care, and Groups Recover Together—have added cannabis-specific tracks since 2024. Insurance coverage remains inconsistent.

For comprehensive clinical and policy background on this issue, see the CannIntel topic hub on high-potency THC and withdrawal effects.